Peripheral NK Cell Count Predicts Response and Prognosis in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Oct 15

PMID 39403373

Authors

Chao Zhang

Fengjia Wu

Xiuqing Lu

Sifen Wang

Minqing Wu

Nian Chen

Shanji Fan

Weidong Wei

Affiliations

Soon will be listed here.

Abstract

Purpose: The count of lymphocyte subsets in blood can reflect the immune status of the body which is closely related to the tumor immune microenvironment and the efficacy of NAT. This study aims to explore the relationship between peripheral blood lymphocyte subsets and the efficacy and prognosis of NAT in breast cancer.

Methods: We retrospectively analyzed clinicopathological information and peripheral blood lymphocyte subpopulation counts of patients receiving NAT from January 2015 to November 2021 at Sun Yat-sen University Cancer Center. Kaplan-Meier curves were used to estimate the survival probability. The independent predictors of NAT response and survival prognosis were respectively analyzed by multivariate logistic regression and Cox regression, and nomograms were constructed accordingly. The prediction efficiency of three nomograms was validated separately in the training cohort and the testing cohort.

Results: 230 patients were included in the study, consisting of 161 in the training cohort and 69 in the testing cohort. After a median follow-up of 1238 days, patients with higher NK cell value showed higher pCR rates and higher OS and RFS after NAT (all < 0.001). Multivariate analyses suggested NK cell count was an independent predictor of NAT response, OS and RFS. We then built nomograms accordingly and validated the prediction performance in the testing cohort (C index for NAT response: 0.786; for OS: 0.877, for RFS: 0.794).

Conclusion: Peripheral blood NK cell count is a potential predictive marker for BC patients receiving NAT. Nomograms based on it might help predict NAT response and prognosis in BC.

References

Zhu Z, Shen H, Xu J, Fang Z, Wo G, Ma Y . GATA3 mediates doxorubicin resistance by inhibiting CYB5R2-catalyzed iron reduction in breast cancer cells. Drug Resist Updat. 2023; 69:100974. DOI: 10.1016/j.drup.2023.100974. View

Das M . Neoadjuvant chemotherapy: survival benefit in gastric cancer. Lancet Oncol. 2017; 18(6):e307. DOI: 10.1016/S1470-2045(17)30321-2. View

Hellmann M, Chaft J, William Jr W, Rusch V, Pisters K, Kalhor N . Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014; 15(1):e42-50. PMC: 4734624. DOI: 10.1016/S1470-2045(13)70334-6. View

Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner B, Weber K . Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2017; 19(1):40-50. DOI: 10.1016/S1470-2045(17)30904-X. View

du Bois A, Baert T, Vergote I . Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer. J Clin Oncol. 2019; 37(27):2398-2405. DOI: 10.1200/JCO.19.00022. View

Zetrini A, Lip H, Abbasi A, Alradwan I, Ahmed T, He C . Remodeling Tumor Immune Microenvironment by Using Polymer-Lipid-Manganese Dioxide Nanoparticles with Radiation Therapy to Boost Immune Response of Castration-Resistant Prostate Cancer. Research (Wash D C). 2023; 6:0247. PMC: 10546607. DOI: 10.34133/research.0247. View

Wu S, Fu T, Jiang Y, Shao Z . Natural killer cells in cancer biology and therapy. Mol Cancer. 2020; 19(1):120. PMC: 7409673. DOI: 10.1186/s12943-020-01238-x. View

Gao F, Xue C, Dong J, Lu X, Yang N, Ou C . Tumor Microenvironment-Induced Drug Depository for Persistent Antitumor Chemotherapy and Immune Activation. Small. 2023; 20(15):e2307736. DOI: 10.1002/smll.202307736. View

Wu Y, Song Y, Wang R, Wang T . Molecular mechanisms of tumor resistance to radiotherapy. Mol Cancer. 2023; 22(1):96. PMC: 10268375. DOI: 10.1186/s12943-023-01801-2. View

10.

Zou Y, Ye F, Kong Y, Hu X, Deng X, Xie J . The Single-Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast Cancer. Adv Sci (Weinh). 2022; 10(5):e2203699. PMC: 9929130. DOI: 10.1002/advs.202203699. View

11.

Alix-Panabieres C, Pantel K . Liquid Biopsy: From Discovery to Clinical Application. Cancer Discov. 2021; 11(4):858-873. DOI: 10.1158/2159-8290.CD-20-1311. View

12.

Tamirisa N, Hunt K . Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. Ann Surg Oncol. 2022; 29(3):1489-1492. DOI: 10.1245/s10434-021-11223-3. View

13.

Zeng Q, He Y, Dong S, Zhao X, Chen Z, Song Z . Optimal cut-off values of BMI, waist circumference and waist:height ratio for defining obesity in Chinese adults. Br J Nutr. 2014; 112(10):1735-44. DOI: 10.1017/S0007114514002657. View

14.

Allison K, Hammond M, Dowsett M, McKernin S, Carey L, Fitzgibbons P . Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020; 38(12):1346-1366. DOI: 10.1200/JCO.19.02309. View

15.

An J, Peng C, Tang H, Liu X, Peng F . New Advances in the Research of Resistance to Neoadjuvant Chemotherapy in Breast Cancer. Int J Mol Sci. 2021; 22(17). PMC: 8431789. DOI: 10.3390/ijms22179644. View

16.

Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Vavassori I, Barni S . Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol. 2013; 65(2):350-7. DOI: 10.1016/j.eururo.2013.06.049. View

17.

Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D . Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2021; 23(1):149-160. PMC: 9455620. DOI: 10.1016/S1470-2045(21)00589-1. View

18.

Dikiy S, Rudensky A . Principles of regulatory T cell function. Immunity. 2023; 56(2):240-255. DOI: 10.1016/j.immuni.2023.01.004. View

19.

Licitra L, Vermorken J . Is there still a role for neoadjuvant chemotherapy in head and neck cancer?. Ann Oncol. 2003; 15(1):7-11. DOI: 10.1093/annonc/mdh001. View

20.

Gentles A, Newman A, Liu C, Bratman S, Feng W, Kim D . The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015; 21(8):938-945. PMC: 4852857. DOI: 10.1038/nm.3909. View